Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Amy K KeatingNathan GossaiChristine L PhillipsKelly MaloneyKristen CampbellAndrew DoanDeepa BhojwaniMichael J BurkeMichael R VernerisPublished in: Blood advances (2020)